Equities

Immunovia AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Immunovia AB (publ)

Actions
Health CareMedical Equipment and Services
  • Price (SEK)0.1822
  • Today's Change-0.005 / -2.67%
  • Shares traded3.70m
  • 1 Year change-48.44%
  • Beta2.4044
Data delayed at least 15 minutes, as of Feb 09 2026 17:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.

  • Revenue in SEK (TTM)785.00k
  • Net income in SEK-125.52m
  • Incorporated2007
  • Employees9.00
  • Location
    Immunovia AB (publ)Medicon Village, Scheelevagen 8LUND 223 63SwedenSWE
  • Phone+46 462756000
  • Websitehttps://immunovia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Scandinavian ChemoTech AB11.68m-8.70m77.01m1.00--13.38--6.59-0.3727-0.37270.50030.26530.7270.59172.661,946,333.00-54.15-92.70-83.07-131.4682.15104.65-74.49-866.060.861-5.610.00--132.6763.8534.96---59.68--
Observe Medical ASA15.60m-115.00m82.40m4.00--3.40--5.28-26.57-26.573.290.19090.11182.878.293,350,800.00-82.38-42.22-205.00-64.146.2430.17-737.14-327.970.1175-3.720.9572---33.85153.47-98.73---2.97--
Iconovo AB1.59m-41.23m83.40m19.00--0.4526--52.56-1.67-1.670.05372.460.0117--0.260863,475.20-30.39-28.39-33.14-31.51901.69159.24-2,598.41-295.86---138.020.0391---58.55-24.2210.36--22.28--
Episurf Medical AB15.60m-62.70m86.28m26.00--0.8064--5.53-0.064-0.0640.01570.06450.1641--3.95577,777.80-65.44-45.67-74.89-50.07-----398.72-857.082.50--0.0844--23.5819.3919.83--6.68--
SyntheticMR AB (publ)51.70m-54.20m103.63m37.00--0.6836--2.00-0.9562-0.95620.96881.700.3737--0.81531,292,550.00-39.171.70-48.162.180.79366.23-104.842.61---18.450.0810.00-37.603.98-260.62--19.19--
Arcoma AB132.94m4.35m108.74m31.0023.711.489.390.8180.32050.32059.875.131.452.9213.714,288,452.004.752.166.663.7540.4537.953.271.402.04--0.000.00-3.813.24336.0011.08-9.43--
Immunovia AB (publ)785.00k-125.52m125.92m9.00------160.41-0.3569-0.35690.0024-0.0210.0156--0.26487,222.22-249.16-48.08-827.53-52.27-7,231.59-6,932.30-15,989.68-17,625.510.6282-3.001.68---40.8921.2075.26------
BibbInstruments AB149.00k-13.30m134.85m4.00--3.16--905.01-0.3802-0.38020.00411.050.00382.062.7137,250.00-33.98-36.85-35.53-40.0630.8759.14-8,922.82-22,555.646.67--0.00-------15.85---1.52--
Scandinavian Real Heart AB0.00-38.87m139.96m12.00--0.8386-----16.17-16.170.0016.690.00----0.00-44.53-27.49-52.77-30.65-------12,518.77----0.0678------49.47--6.59--
Scandinavian Medical Solutions A/S350.30m37.11k141.68m28.005,409.091.2011.340.40440.00070.00078.882.991.291.9411.19--0.01376.590.024611.6823.1224.880.01064.680.35241.140.4345--8.2842.38-99.67-64.34----
Bioretec Oy-1.07tn-1.07tn149.70m57.00---------------------------57.56---77.31--70.90---128.20--------16.3221.07-21.78------
iZafe Group AB5.90m-17.73m161.89m10.00--9.83--27.43-0.0614-0.06140.01940.04520.17573.448.15843,000.00-52.78-57.76-73.42-72.44-106.29-287.24-300.41-630.900.9122-17.450.0198--336.55-11.1036.26---24.50--
Bactiquant A/S11.79m-18.67m165.74m----11.37--14.06-0.4696-0.46960.29660.27230.46562.6915.14---73.73-55.41-85.85-64.53-31.80-10.94-158.37-121.813.26-9.700.1926---41.68-14.27-4.72------
Ortivus AB75.91m-24.74m168.25m34.00------2.22-0.5583-0.55831.71-0.50621.186.7716.222,372,281.00-38.46-4.62-147.30-8.6534.7941.27-32.59-3.550.4719-4.011.72---4.369.60-36.49--65.37--
BrainCool AB (publ)43.62m-36.85m177.70m20.00--1.00--4.07-0.1408-0.14080.16660.44790.28411.152.922,180,769.00-24.00-38.93-26.22-53.1029.8648.00-84.48-233.832.29-33.110.00--72.0556.5028.13--4.34--
Micropos Medical AB (publ)8.46m-20.21m178.15m9.00--8.99--21.05-0.1296-0.12960.05380.11910.3797-0.00315.091,057,905.00-90.68-74.98-115.26-98.65100.1587.53-238.83-670.954.49-70.700.00--133.4736.607.09------
Data as of Feb 09 2026. Currency figures normalised to Immunovia AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

3.49%Per cent of shares held by top holders
HolderShares% Held
Handelsbanken Fonder ABas of 31 Jan 202615.50m2.30%
SEB Funds ABas of 31 Dec 20253.96m0.59%
Abante Asesores Gesti�n SGIIC SAas of 31 Dec 20253.42m0.51%
Banor Capital Ltd.as of 31 Mar 2024517.78k0.08%
Storebrand Asset Management ASas of 30 Nov 202597.22k0.01%
Coeli Asset Management ABas of 31 Dec 20240.000.00%
More ▼
Data from 30 Sep 2025 - 06 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.